scholarly journals Recent advances in managing and understanding pyoderma gangrenosum

F1000Research ◽  
2019 ◽  
Vol 8 ◽  
pp. 2092 ◽  
Author(s):  
Josh Fletcher ◽  
Raed Alhusayen ◽  
Afsaneh Alavi
Keyword(s):  
Pyoderma Gangrenosum ◽  
Randomized Clinical Trials ◽  
Traditional Approach ◽  
Wound Care ◽  
Case Reports ◽  
Case Series ◽  
Adaptive Immune System ◽  
Neutrophilic Dermatosis ◽  
Recent Advances ◽  
No Gold Standard

Pyoderma Gangrenosum (PG) is a rare neutrophilic dermatosis with multiple different clinical presentations and associated comorbidities. PG has historically been a challenging disorder to diagnose, leading to the development of new diagnostic criteria rather than the traditional approach of a diagnosis of exclusion. The pathophysiology is thought to involve both innate and adaptive immune system dysregulation, neutrophilic abnormalities, environmental, and genetic factors. As of today, no gold standard therapy exists for the treatment of PG, and the literature is restricted to mainly case reports, case series, and 2 small randomized clinical trials. Topical, systemic, and biologic therapy, as well as adequate analgesia and proper wound care all play a role in the management of PG. Recent studies have identified additional cytokines and signalling cascades thought to be involved in the pathogenesis of PG, ultimately leading to the development of new targeted therapies. This review will focus on recent advances in the pathophysiology, clinical presentation and associated comorbidities, diagnosis, and management of PG.

scholarly journals Russian-language publication activities of medical researchers during the COVID-19 pandemic: results of the year

2021 ◽  
Vol 26 (4) ◽  
pp. 4451
Author(s):  
O. T. Kim ◽  
O. M. Drapkina ◽  
Yu. V. Rodionova
Keyword(s):  
Randomized Clinical Trials ◽  
Case Reports ◽  
Case Series ◽  
Healthcare Management ◽  
Russian Language ◽  
Original Research ◽  
Global Trends ◽  
Pubmed Database ◽  
Number Of Publications ◽  
Study Designs

Aim. To study the dynamics and patterns of medical publications in Russian, made during the year from February 2020, in order to assess the completeness of data on the etiology, pathogenesis, prevention and treatment of coronavirus disease 2019 (COVID-19), as well as rehabilitation and healthcare management during a pandemic.Material and methods. We searched for publications using the Pubmed database and the Elpub platform. The search was carried out using the following requests: “COVID-19” and “SARS-CoV-2”. Thematic sections were allocated according to source type, specialization and research design. The publications were classified according to keywords and meaning. The publication time was estimated by the date it was accepted for publication. Values were assessed using numerical values and graphs.Results. One hundred fifteen (28,5%) publications presented data from original research, while 288 (71,5%) — reflected the results of already existing sources. An increase in proportion of primary sources with the pandemic spread was established. There were following most common study designs: case series — 87 (77,7%); case reports — 15 (13,4%); cohort studies — 8 (7,1%); randomized clinical trials — 2 (1,8%). By topic, the largest number of articles are devoted to the diagnosis and treatment of COVID-19 — 250 (62%), epidemiology — 36 (8,9%), etiology and pathogenesis — 36 (8,9%), healthcare management — 30 (7,4%), “Other” — 20 (4,9%), and policy papers from expert communities — 13 (3,25%). The smallest number of publications is directly related to cardiology and prevention, including immunoprophylaxis — 12 (2,9%), as well as rehabilitation — 6 (1,5%).Conclusion. The dynamics and patterns of publications on COVID-19 in Russian are generally in line with global trends and reflect the pandemic characteristics in Russia. Due to disease novelty, there is currently a knowledge gap in the treatment, prevention and long-term outcomes of COVID-19. In the future, studies with a higher evidence level are needed on possible methods of treatment, prevention, including cardiology issues and vaccination, as well as rehabilitation.

scholarly journals Profile of Scientific Production on Ankyloglossia

2020 ◽  
pp. 1-13
Author(s):  
Roberta Lopes de Castro Martinelli ◽  
Reinaldo Jordão Gusmão ◽  
María Paz Moya Daza ◽  
Irene Queiroz Marchesan ◽  
Giédre Berretin-Felix
Keyword(s):  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Case Reports ◽  
Case Series ◽  
Scientific Production ◽  
Publication Type ◽  
Level Of Evidence ◽  
First Results ◽  
Bibliometric Review

This work aims to describe the profile of scientific production referring to ankyloglossia. For this an investigation was carried out by searching for scientific articles indexed in the electronic databases LILACS and PUBMED. For the bibliometric review, the data referring to the year of publication, type of study and level of evidence were examined and tabulated. The data were discussed on the quantitative and representative values optics. The first results allowed to analyzic 651 published studies were analyzed. Most of the research on tongue tie found correspond to descriptive studies and case series (49.31%), followed by case reports, in vitro research, in animals and literature review (24.27%), cohort and cases and controls (11.98%), specialist opinion (11.68%), randomized clinical trials (1.54%) and systematic reviews (1.22%). Few studies addressed complications during or after lingual frenulum release surgery. In conclusion Scientific production on ankyloglossia has shown an increasing increase in the last 28 years, with studies with evidence levels 1, 2 and 3 being published, whose main focus was the performance of surgery to release the lingual frenulum.

scholarly journals Pyoderma Gangrenosum with Positive Antinuclear Antibody, in the Absence of Systemic Association

2018 ◽  
Vol 16 (1) ◽  
pp. 66-69
Author(s):  
Smriti Shrestha ◽  
Alisha Aryal
Keyword(s):  
Pyoderma Gangrenosum ◽  
Lupus Erythematosus ◽  
Antinuclear Antibody ◽  
Case Reports ◽  
Neutrophilic Dermatosis ◽  
Systemic Diseases ◽  
Connective Tissue Disorders ◽  
Systemic Lupus ◽  
Unique Case ◽  
Positive Antinuclear Antibody

Pyoderma gangrenosum is an uncommon neutrophilic dermatosis, seen on legs, and infrequently on hands and other anatomical sites. It is associated with systemic diseases in 50-70% of the cases. Antinuclear antibody (ANA) seropositivity has been reported in pyoderma gangrenosum associated with connective tissue disorders. However, there are very few case reports of pyoderma gangrenosum in patients of systemic lupus erythematosus, while we did not find any reports of ANA seropositivity in isolated pyoderma gangrenosum. Hence, we report this unique case of pyoderma gangrenosum with classical clinicohistopathology, positive ANA but no systemic association. As anticipated, our patient responded promptly to steroids.

scholarly journals Takayasu arteritis with pyoderma gangrenosum: case reports and literature review

2019 ◽  
Vol 3 (1) ◽  
Author(s):  
Xuehan Zhang ◽  
Yang Jiao
Keyword(s):  
Pyoderma Gangrenosum ◽  
Takayasu Arteritis ◽  
Case Reports ◽  
Disease Process ◽  
Skin Lesions ◽  
Clinical Severity ◽  
Chinese Patients ◽  
Neutrophilic Dermatosis ◽  
American College Of Rheumatology ◽  
Pubmed Database

Abstract Background Takayasu arteritis is a rare, chronic inflammatory arteriopathy affecting mainly the aorta and its branches. Many skin manifestations have been reported in association with this disease. Pyoderma gangrenosum is a skin complication that is a neutrophilic dermatosis characterized by destructive, necrotizing and noninfective skin infiltration. However, there are no related records on these conditions in Chinese patients. Case presentation We reported two Chinese female patients presenting with pyoderma gangrenosum associated with Takayasu arteritis. Pyoderma gangrenosum preceded Takayasu arteritis in both patients. Their skin lesions were diagnosed as pyoderma gangrenosum through skin biopsy and relieved after treating with steroids and immunosuppressants. During the follow-up, both patients developed symptoms caused by vascular stenosis and occlusion, such as dizziness and weakness of upper limb. The results of aortic angiography revealed multiple large arteries narrowed and blocked. According to the criteria of the American College of Rheumatology, the vasculitis in both patients were classified as Takayasu arteritis. Since there was scant evidence of active inflammation and the skin lesions were stable, neither of them was given strong immnosuppressive therapy. The PubMed database was also searched and 16 related well-documented cases of Takayasu with pyoderma gangrenosum were reviewed and summarized. Conclusions Pyoderma gangrenosum could occur at any stage of the Takayasu arteritis disease process. No correlation was found between the location of the skin lesions and the clinical severity and scope of Takayasu arteritis. It is important to remember the rare possibility of Takayasu arteritis in patients with skin lesions indicative of pyoderma gangrenosum of unknown aetiology. Obtaining the relevant history and regular monitoring of the arteries are necessary.

Evidence and the main adverse effects regarding drug therapies in the war against COVID-19

2020 ◽  
Vol 27 ◽  
Author(s):  
Mauricio Mora-Ramírez ◽  
Paulina Melgoza-Hernández ◽  
Sebastian Eduardo Toledo-Ramírez ◽  
Juan Manuel Mejía Aranguré
Keyword(s):  
Adverse Effects ◽  
Drug Targets ◽  
English Language ◽  
Randomized Clinical Trials ◽  
Case Reports ◽  
Case Series ◽  
Pharmacological Therapy ◽  
Rapid Review ◽  
Definitive Therapy ◽  
Potential Drug Targets

Background: Nowadays, the breakthrough of COVID-19 pandemic around the world is the biggest health challenge for the clinicians, and it represents an unexpected effort to identify effective treatment for those patients. No proven definitive therapies for this infection currently exist. Unfortunately, the infected patients increased in an alarming way every day, faster than medical evidence. At present, the expanding knowledge regarding SARS-COV-2 virology provides several potential drug targets. Objective: Therefore, clinicians need a rapid review and guideline about the main adverse effects regarding the most prescribed drugs and, specifically, the efficacy and potential risk of each pharmacological therapy, during hospital care. Methods: The articles review was performed using PubMed to identify relevant papers in English language reported through July 20th, 2020; a second review was performed using Web of Science until August 28th. Due to the lack of randomized clinical trials, we included case reports, case series, and reviews. We found 1606 total articles related. The authors independently reviewed the titles and abstracts for inclusion. Conclusion: At present, despite the enormous medical effort for publishing several trials or case reports, we have not yet discovered a definitive therapy against the COVID-19 infection. This brief review aims to prompt identification of risk factors and main adverse effects in a systematic view related to therapy with partial evidence proposed to date.

scholarly journals Pyoderma gangrenosum ‒ cutaneous and extracutaneous manifestations

2019 ◽  
Vol 1 (1) ◽  
pp. 7-9
Author(s):  
Klaudia Dopytalska ◽  
Piotr Sobolewski ◽  
Marek Roszkiewicz ◽  
Agata Mikucka-Wituszyńska ◽  
Elżbieta Szymańska ◽  
...  
Keyword(s):  
Pain Management ◽  
Pyoderma Gangrenosum ◽  
Inflammatory Bowel Diseases ◽  
Wound Care ◽  
Neutrophilic Dermatosis ◽  
Biological Therapies ◽  
Haematological Malignancies ◽  
Cutaneous Lesions ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Pyoderma gangrenosum (PG) is a rare, neutrophilic dermatosis with extracutaneous manifestations and associated systemic disorders, including inflammatory bowel diseases, arthritis and haematological malignancies. The pathogenesis of PG is still not fully understood. The cutaneous lesions are often polymorphic and include papules, nodules, sterile pustules with erythematous induration, which quickly evolve into necrotic painful ulcerations. PG can also affect lungs, spleen, liver, pancreas, kidneys, bones and eyes. The treatment of PG is long and challenging and involves the use of sytemic corticoteroids, immunosupressive drugs and biological therapies with concomitant pain management and wound care.

scholarly journals Guidelines for the Use of Cannabinoid Compounds in Chronic Pain

2005 ◽  
Vol 10 (suppl a) ◽  
pp. 44A-46A ◽  
Author(s):  
AJ Clark ◽  
ME Lynch ◽  
M Ware ◽  
P Beaulieu ◽  
IJ McGilveray ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Case Reports ◽  
Case Series ◽  
Practical Approach ◽  
National Library ◽  
Off Label ◽  
Cannabinoid Compounds

OBJECTIVE: To provide clinicians with guidelines for the use of cannabinoid compounds in the treatment of chronic pain.METHODS: Publications indexed from 1990 to 2005 in the National Library of Medicine Index Medicus were searched through PubMed. A consensus concerning these guidelines was achieved by the authors through review and discussion.RESULTS: There are few clinical trials, case reports or case series concerning the use of cannabinoid compounds in the treatment of chronic pain. There are no randomized clinical trials examining the use of herbal cannabis in the treatment of chronic pain.CONCLUSIONS: A practical approach to the treatment of chronic pain with cannabinoid compounds is presented. Specific suggestions about the off-label dosing of nabilone (Cesamet, Valeant Canada limitée/Limited) and dronabinol (Marinol, Solvay Pharma Inc, Canada) in the treatment of chronic pain are provided.

scholarly journals Cannabinoids in the Treatment of Parkinson’s Disease

2017 ◽  
Vol 01 (04) ◽  
pp. E307-E311 ◽  
Author(s):  
Florin Gandor ◽  
Georg Ebersbach
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Single Case ◽  
Case Reports ◽  
Therapeutic Option ◽  
Case Series ◽  
Idiopathic Parkinson’S Disease ◽  
Idiopathic Parkinson's Disease

AbstractDue to the changing legal status of medical cannabis and derivatives in numerous countries, this therapeutic option has moved into the field of public debate. Neurologists treating patients with idiopathic Parkinson’s disease are increasingly confronted with questions regarding cannabis as a treatment alternative, especially for levodopa-resistant Parkinson’s symptoms. A number of single case reports and case series suggested improvement of Parkinsonian symptoms after cannabinoid intake, but the small number of available randomized clinical trials failed to reproduce the extent of these findings. Only one trial found a reduction of levodopa-induced dyskinesia with cannabinoid treatment, the remaining three trials showed no effect on Parkinsonian symptoms. This article gives an overview on the effects of cannabis, and reviews experimental and clinical trials studying the effects of cannabinoids in idiopathic Parkinson’s disease.

scholarly journals Narrow Diameter Dental Implants as an Alternative Treatment for Atrophic Alveolar Ridges. Systematic Review and Meta-Analysis

Materials ◽  
2021 ◽  
Vol 14 (12) ◽  
pp. 3234
Author(s):  
Georgina González-Valls ◽  
Elisabet Roca-Millan ◽  
Juan Manuel Céspedes-Sánchez ◽  
Beatriz González-Navarro ◽  
Aina Torrejon-Moya ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Bone Loss ◽  
Dental Implants ◽  
Randomized Clinical Trials ◽  
Case Reports ◽  
Case Series ◽  
Small Diameter ◽  
Sufficient Evidence ◽  
Failure Rates ◽  
Marginal Bone Loss

To determine the marginal bone loss and the survival, success and failure rates of narrow dental implants, a systematic literature search was carried out in the MEDLINE (Pubmed), Cochrane, Scopus, and Scielo databases for articles published between 2010 and 2021. The exclusion criteria were: systematic reviews, case reports, expert opinions; animal studies; samples of less than 10 subjects; follow-up periods of less than 36 months; smokers of minimum 10 cigarettes/day; and articles about mini-implants for orthodontic anchorage. Meta-analyses were performed to assess marginal bone loss and implant survival, success, and failure rates. Fifteen studies were included: 7 clinical trials, 3 randomized clinical trials, 3 cohort studies, and 2 case series. The total number of subjects was 773, in whom 1245 implants were placed. The survival rate for the narrow diameter implants was 97%, the success rate 96.8%, and the failure rate 3%. Marginal bone loss was 0.821 mm. All these data were evaluated at 36 months. Based on the literature, it can be considered that there is sufficient evidence to consider small diameter implants a predictable treatment option. These show favorable survival and success rates and marginal bone loss. All of them are comparable to those of standard diameter dental implants.

scholarly journals Management of Darier disease: A review of the literature and update

2021 ◽  
Vol 87 ◽  
pp. 14-21
Author(s):  
Roger N. Haber ◽  
Nicole G. Dib
Keyword(s):  
Clinical Trials ◽  
Therapeutic Approach ◽  
Randomized Clinical Trials ◽  
Case Reports ◽  
Case Series ◽  
Small Sample ◽  
Treatment Modalities ◽  
Published Data ◽  
Clinical Images ◽  
Darier Disease

Darier disease (DD) is a rare type of inherited keratinizing disorder with no definitive therapeutic approach. The objective of this study is to provide a detailed literature review of all the available treatment modalities of Darier disease, including those that are both surgical and non surgical, to compare their efficacies and to propose a novel therapeutic approach. A complete search of the literature for all articles describing the different treatments of Darier disease, with no restrictions on patients’ ages, gender or nationalities, was performed with the use of PubMed. A total of 68 articles were included in the study: 3 prospective studies, 44 case reports/case series and 21 letters/correspondences/clinical images. The treatments described were topical, oral or physical. Retinoids (isotretinoin, tazarotene and adapalene) and fluorouracil were the two most effective topical treatments. Oral retinoids were the most effective oral therapy and were prescribed in the cases of generalized Darier disease. For localized and resistant skin lesions, physical therapies including surgical excision, dermabrasion and CO2 laser ablation were the first line choices. Limitations of this article include the inability to verify the accuracy of the published data, the relatively small sample size, the absence of randomized controlled clinical trials and possible unidentified confounding factors in various studies. In every therapeutic approach to Darier disease, consideration of patient comorbidities, disease distribution, severity and treatment accessibility is essential. Large and randomized clinical trials are necessary for the comparison of the efficacy and the safety of all the treatments of Darier disease and settling a consensus for management.

Sign in / Sign up

Export Citation Format

Share Document